Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;33(10):2527-2530.
doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13.

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry A Rogers  1 , Luay Mousa  1 , Qiuhong Zhao  1 , Seema A Bhat  1 , John C Byrd  1 , Zeinab El Boghdadly  2 , Tomas Guerrero  3 , Lauren B Levine  4 , Fabienne Lucas  1 , Polina Shindiapina  1 , Audrey M Sigmund  1 , Matthew Sullivan  3 , Tracy E Wiczer  4 , Jennifer A Woyach  5 , Farrukh T Awan  1
Affiliations

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry A Rogers et al. Leukemia. 2019 Oct.
No abstract available

PubMed Disclaimer

References

    1. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017. April 20; 129(16): 2224–2232. - PMC - PubMed
    1. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med 2015. April 09; 372(15): 1430–1440. - PubMed
    1. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013. July 4; 369(1): 32–42. - PMC - PubMed
    1. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013. August 08; 369(6): 507–516. - PMC - PubMed
    1. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 2017. June 12; 31(6): 833–843 e835. - PMC - PubMed

Publication types